Patent · US Expired

Alpha 1a adrenergic receptor antagonist

US5807856A · kind A · utility

7Cited by
5References
12Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 12, 1996
Grant dateSep 15, 1998
Priority date
Expiry dateNov 12, 2016

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D417/06
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as selective alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing orthostatic hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.